Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases utilizing its proprietary technology platform. The company is recognized for its ability to provide rapid and precise testing, which enhances clinical decision-making and improves patient outcomes. With a strong commitment to ongoing research and development, Alamar is well-positioned to address pressing medical needs, making it an appealing investment opportunity for institutional investors looking to capitalize on growth within the expanding diagnostics market.
| Revenue (TTM) | $87.16M |
| Gross Profit (TTM) | $49.77M |
| EBITDA | $-32.09M |
| Operating Margin | -47.40% |
| Return on Equity | -33.60% |
| Return on Assets | -13.50% |
| Revenue/Share (TTM) | $7.39 |
| Book Value | $-2.57 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 19.65 |
| EV/Revenue | 19.83 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 98.90% |
| Shares Outstanding | $69.31M |
| Float | $36.08M |
| % Insiders | 26.68% |
| % Institutions | 35.50% |
Volatility is currently contracting
Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging
FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the second quarter 2026 after market close on Monday, August 10, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. | Resulting dataset will be publicly accessible, linked through National Alzheimer's Coordinating Center IDs and open to AI-driven discovery through a national data challenge. | Project is part of the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) portfolio, leveraging academic, philanthropic, and data-sharing partnerships for large-scale biomarker discovery. National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. | Resulting dataset will be publicly accessible, linked through National Alzheimer's Coordinating Center IDs and open to AI-driven discovery through a national data challenge. | Project is part of the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) portfolio, leveraging academic, philanthropic, and data-sharing partnerships for large-scale biomarker discovery.
Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer's disease detection and staging Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer's disease detection and staging
eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer's disease | Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program | Data to be featured in Alamar's workshop at AAIC 2026 eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer's disease | Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program | Data to be featured in Alamar's workshop at AAIC 2026
NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices | Workflow extends NULISA into longitudinal, decentralized, and population-scale research NULISA™ DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices | Workflow extends NULISA into longitudinal, decentralized, and population-scale research
FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026.
FREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will be participating in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, Nevada.
FREMONT, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will publish its first quarter 2026 financial results before market open on Friday, May 8, 2026.
FREMONT, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (“Alamar”), a leader in Precision Proteomics dedicated to advancing the early detection of disease, today announced the closing of its upsized initial public offering of 12,937,500 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase an additional 1,687,500 shares of common stock, at a public offering price of $17.00 per share, less underwriting discounts and commissions. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Alamar, were approximately $219.9 million. The shares began trading on the Nasdaq Global Select Market on April 17, 2026 under the ticker symbol “ALMR.”
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALMR and any ticker you trade — then tracks every position and per-strategy win rate.
